These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 22820440)

  • 1. Second-line 90Yttrium-ibritumomab tiuxetan (Zevalin) in a patient with conjunctival mucosa-associated lymphoid tissue lymphoma refractory to rituximab.
    Oellers P; Savar A; Samaniego F; Pro B; Esmaeli B
    Ophthalmic Plast Reconstr Surg; 2012; 28(6):e145-6. PubMed ID: 22820440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 90Y-ibritumomab tiuxetan (Zevalin) in heavily pretreated patients with mucosa associated lymphoid tissue lymphoma.
    Hoffmann M; Troch M; Eidherr H; Traub-Weidinger T; Jonak C; Muellauer L; Raderer M
    Leuk Lymphoma; 2011 Jan; 52(1):42-5. PubMed ID: 21133720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of ⁹⁰Yttrium-ibritumomab tiuxetan in relapsed/refractory extranodal marginal-zone lymphoma.
    Vanazzi A; Grana C; Crosta C; Pruneri G; Rizzo S; Radice D; Pinto A; Calabrese L; Paganelli G; Martinelli G
    Hematol Oncol; 2014 Mar; 32(1):10-5. PubMed ID: 23696416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of combination therapy with fludarabine, mitoxantrone, and rituximab followed by yttrium-90 ibritumomab tiuxetan and maintenance rituximab as front-line therapy for patients with follicular or marginal zone lymphoma.
    Karmali R; Kassar M; Venugopal P; Shammo JM; Fung HC; Bayer R; O'Brien T; Gregory SA
    Clin Lymphoma Myeloma Leuk; 2011 Dec; 11(6):467-74. PubMed ID: 21700527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma.
    Esmaeli B; McLaughlin P; Pro B; Samaniego F; Gayed I; Hagemeister F; Romaguera J; Cabanillas F; Neelapu SS; Banay R; Fayad L; Wayne Saville M; Kwak LW
    Ann Oncol; 2009 Apr; 20(4):709-14. PubMed ID: 19150940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Yttrium-90 ibritumomab tiuxetan-induced complete remission in a patient with classical lymphocyte-rich Hodgkin's Lymphoma.
    Schnell R; Dietlein M; Schomäcker K; Kobe C; Borchmann P; Schicha H; Hallek M; Engert A
    Onkologie; 2008 Feb; 31(1-2):49-51. PubMed ID: 18268399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
    Witzig TE; Gordon LI; Cabanillas F; Czuczman MS; Emmanouilides C; Joyce R; Pohlman BL; Bartlett NL; Wiseman GA; Padre N; Grillo-López AJ; Multani P; White CA
    J Clin Oncol; 2002 May; 20(10):2453-63. PubMed ID: 12011122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Extranodal marginal zone lymphoma of the ocular adnexa].
    Møller A; Specht L; Toft PB; Sjø LD
    Ugeskr Laeger; 2008 Nov; 170(45):3660-3. PubMed ID: 18986616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma.
    Witzig TE; Flinn IW; Gordon LI; Emmanouilides C; Czuczman MS; Saleh MN; Cripe L; Wiseman G; Olejnik T; Multani PS; White CA
    J Clin Oncol; 2002 Aug; 20(15):3262-9. PubMed ID: 12149300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I study of 90yttrium-ibritumomab-tiuxetan in children and adolescents with relapsed/refractory CD20-positive non-Hodgkin's lymphoma: a Children's Oncology Group study.
    Cooney-Qualter E; Krailo M; Angiolillo A; Fawwaz RA; Wiseman G; Harrison L; Kohl V; Adamson PC; Ayello J; vande Ven C; Perkins SL; Cairo MS;
    Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5652s-5660s. PubMed ID: 17875803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Full-dose 90Y ibritumomab tiuxetan therapy is safe in patients with prior myeloablative chemotherapy.
    Jacobs SA; Vidnovic N; Joyce J; McCook B; Torok F; Avril N
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7146s-7150s. PubMed ID: 16203814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
    Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA
    J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of (90)Y Ibritumomab tiuxetan (Zevalin) in patients with previously untreated marginal zone lymphoma.
    Lossos IS; Fabregas JC; Koru-Sengul T; Miao F; Goodman D; Serafini AN; Hosein PJ; Stefanovic A; Rosenblatt JD; Hoffman JE
    Leuk Lymphoma; 2015 Jun; 56(6):1750-5. PubMed ID: 25315074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Yttrium-90 ibritumomab tiuxetan followed by rituximab maintenance as treatment for patients with diffuse large B-cell lymphoma are not candidates for autologous stem cell transplant.
    Arnason JE; Luptakova K; Rosenblatt J; Tzachanis D; Avigan D; Zwicker JI; Levine J; Kim M; Parker JA; Grant B; Joyce RM
    Acta Haematol; 2015; 133(4):347-53. PubMed ID: 25677780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [90Y-ibritumomab tiuxetan in patients with follicular lymphoma relapsing or refractory to rituximab].
    Aurer I; Huić D; Zuvić M; Sever-Prebilić M; Ajduković R; Radman I; Skare-Librenjak L; Ostojić-Kolonić S; Labar B
    Lijec Vjesn; 2006; 128(7-8):224-7. PubMed ID: 17087138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab monotherapy as a first-line treatment for pulmonary mucosa-associated lymphoid tissue lymphoma.
    Okamura I; Imai H; Mori K; Ogura K; Isoda A; Mihara K; Matsumoto M; Saito R; Takahashi T; Ikeda T
    Int J Hematol; 2015 Jan; 101(1):46-51. PubMed ID: 25378228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab plus short-duration chemotherapy followed by Yttrium-90 Ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium.
    Hainsworth JD; Spigel DR; Markus TM; Shipley D; Thompson D; Rotman R; Dannaher C; Greco FA
    Clin Lymphoma Myeloma; 2009 Jun; 9(3):223-8. PubMed ID: 19525191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A case of conjunctival MALT lymphoma: successfully treated with solely extended rituximab therapy.
    Celiker H; Toker E; Kaygusuz Atagunduz I
    Int Ophthalmol; 2019 Mar; 39(3):687-691. PubMed ID: 29411260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transformation of MALT lymphoma to pure plasma cell histology following treatment with the anti-CD20 antibody rituximab.
    Woehrer S; Streubel B; Chott A; Hoffmann M; Raderer M
    Leuk Lymphoma; 2005 Nov; 46(11):1645-9. PubMed ID: 16236618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regression of pulmonary MALT lymphoma after treatment with rituximab.
    Chong EA; Svoboda J; Cherian S; Andreadis C; Downs LH; Zhuang H; Alavi A; Tsai DE; Schuster SJ
    Leuk Lymphoma; 2005 Sep; 46(9):1383-6. PubMed ID: 16109620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.